ArticleBMC nephrology2021
Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort.
Article in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Prevalence and determinants of poor outcome in patients with chronic kidney disease in low-income countries in sub-Saharan Africa: a systematic review.The Pan African medical journal · 2026Pooled it
- Blood lead exposure, renal hyperfiltration, and accelerated kidney function decline among people living with HIV in northern Tanzania: A longitudinal cohort study.Toxicology reports · 2026Article
- Factors associated with circulating levels of IL-17A in a high HIV-burden population.Scientific reports · 2026Article
- Article
- Evaluation of CRP SNV rs2808630 and acute proinflammatory biomarkers in patients with CKD and PLHIV with CKD: a case-control study.BMC nephrology · 2025Article
- Sequelae of Immunocompromised Host Pneumonia.Clinics in chest medicine · 2025Review
- Non-Communicable Diseases in Patients with Human Immunodeficiency Virus and Their Risk Factors.Infection & chemotherapy · 2025Article
- Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.International journal of molecular sciences · 2025Article
- Article
- Article
- Kidney disease among adults on tenofovir-based second-line antiretroviral therapy in Dar es Salaam, Tanzania.Southern African journal of HIV medicine · 2025Article
- Prevalence and associations of chronic kidney disease among antiretroviral therapy-naïve persons living with HIV in Lagos, Nigeria.BMC nephrology · 2024Article
- Article
- Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.AIDS research and therapy · 2024Article
- HIV and Substance Use in Latin America: A Scoping Review.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV subjects have several kidney pathologies, like HIV-associated nephropathy or antiretroviral therapy injury, among others. The global prevalence of Chronic Kidney Disease (CKD) is 8-16%; however, in HIV subjects, the prevalence varies between geographic regions (2-38%). The aim was to determine the prevalence of CKD and identify the associated risk factors.
methodsA longitudinal descriptive study was carried out at the 'Hospital Civil de Guadalajara' Feb'18 - Jan'19. Basal clinical, demographic, opportunistic infections (OI), and laboratory data were obtained at months 0 and 3; inclusion criteria were ≥ 18 years old, naïve HIV + , urine albumin/creatinine ratio, serum creatinine & urine test, and signed informed consent. Descriptive and multiple logistic regression statistical analyses were made.
resultsOne hundred twenty subjects were included; 92.5% were male, 33 ± 9.5 years, 60% consumed tobacco, 73% alcohol, and 59% some type of drug. The CKD prevalence was 15.8%. CKD patients had a higher risk of hepatitis C virus coinfection, Relative Risk (RR):5.9; HCV infection, RR:4.3; ≥ 30 years old, RR:3.9; C clinical-stage, RR:3.5; CD4
conclusionsOur study showed a higher CKD prevalence in patients with HIV; higher CKD development with coinfections as Hepatitis C Virus and Mycobacterium tuberculosis. The identification and prompt management of CKD and coinfections should be considered to avoid the progression and to delay renal replacement therapy as long as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.